These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35307793)

  • 1. The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
    Chaudhuri KR; Pickard AS; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Bao Y; Sus J; Jones G; Ridley C; Oddsdottir J; Najle-Rahim S; Madin-Warburton M; Xu W; Schrag A
    Pharmacoeconomics; 2022 May; 40(5):559-574. PubMed ID: 35307793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
    Pahwa R; Merola A; Soileau M; Alobaidi A; Pickard AS; Kandukuri PL; Bao Y; Strezewski J; Oddsdottir J; Xu W; Standaert D
    Mov Disord; 2023 Dec; 38(12):2308-2312. PubMed ID: 37877478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
    Zhang XR; Jiang ZY; Zhang ZR; Chen HJ; Wu K; He JC; Xie CL
    Drug Des Devel Ther; 2020; 14():845-854. PubMed ID: 32161444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.
    Chaudhuri KR; Kovács N; Pontieri FE; Aldred J; Bourgeois P; Davis TL; Cubo E; Anca-Herschkovitsch M; Iansek R; Siddiqui MS; Simu M; Bergmann L; Ballina M; Kukreja P; Ladhani O; Jia J; Standaert DG
    J Parkinsons Dis; 2023; 13(5):769-783. PubMed ID: 37302039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
    Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
    J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
    Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
    Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review.
    Imamura A; Kuroyanagi G; Usami T; Sato T; Horiba M; Sakai H; Takahashi A; Ueki Y; Matsukawa N; Murakami H
    Orthop Surg; 2023 Nov; 15(11):2993-2999. PubMed ID: 37712322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E
    Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Artificial Neural Network Predicts Gender Differences of Motor and Non-Motor Symptoms of Patients with Advanced Parkinson's Disease under Levodopa-Carbidopa Intestinal Gel.
    Bougea A; Derikvand T; Efthimiopoulou E
    Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.